![Santosh Kesari MD, PhD, FANA, FAAN](https://res.cloudinary.com/els-assets/image/upload/f_auto,w_120,c_thumb,ar_1:1,g_face/r_max,bo_2px_solid_rgb:d3d3d37F/practice-update/default/board-member.jpg)
Santosh Kesari MD, PhD, FANA, FAAN
Professor and Chair, Department of Translational Neuro-Oncology and Neurotherapeutics, John Wayne Cancer Institute; Director, Neuro-Oncology, Providence St. John’s Health Center, Santa Monica, CaliforniaDr. Santosh Kesari is the Chair of the Department of Translational Neuro-Oncology and Neurotherapeutics at the John Wayne Cancer Institute and Director of Neuro-Oncology at Providence St. John’s Health Center in Santa Monica, California. A Fellow of the American Neurological Association (FANA) and a Fellow of the American Academy of Neurology (FAAN), he is a member of the Los Angeles Biomedical Research Institute.
Dr. Kesari is very active in basic and translational research and clinical research. His research program is focused on understanding the developmental and molecular aberrations resulting in malignant gliomas and using this information to develop novel molecular therapeutics to improve patient survival. He has published his research in over 160 articles in peer-reviewed journals.
Dr. Kesari was awarded his medical degree from the University of Pennsylvania, where he also earned a PhD in molecular biology. He was a resident in neurology at the Partners Neurology Residency Program of the Massachusetts General and Brigham and Women’s hospitals, Boston, Massachusetts, after which he completed a clinical fellowship in neuro-oncology at the Dana-Farber Cancer Institute/Massachusetts General Hospital/Brigham and Women's Hospital in Boston.
He is a member of the Society for Neuroscience, American Academy of Neurology, American Society of Clinical Oncology, American Association for Cancer Research among other professional organizations. He is a peer reviewer for over 100 national and international scientific journals and serves on a number of editorial review boards.
Recent Contributions to PracticeUpdate:
- Circulating Tumor DNA in Patients With Brain Tumors
- Locally Administered IL4 Guided Toxin for Recurrent Glioblastoma
- Marizomib and Temozolomide With Radiotherapy for Patients With Newly Diagnosed GBM
- Current Concepts in Therapeutic Selection for Brain Metastases
- Glioblastoma Therapeutic Review From SNO 2017
- Patient-Related Factors and Issues in Using TTFields for Glioblastoma
- Translational Medicine in NeuroOncology: Progress in Meeting Unmet Needs
- Practice Changers from SNO 2016: A Discussion with Santosh Kesari